Crinecerfont (NBI-74788)
Congenital Adrenal Hyperplasia
Phase 3Active
Key Facts
About Neurocrine Biosciences
Founded in 1992, Neurocrine Biosciences has evolved from a research-focused biotech into a successful commercial company with over $1.5 billion in annual revenue. Their expertise in neuroscience drug development has produced breakthrough treatments like INGREZZA for tardive dyskinesia and a promising pipeline including programs for Parkinson's disease, schizophrenia, and endometriosis. The company combines strong commercial execution with continued innovation in CNS therapeutics.
View full company profile